Rutgers, Robert Wood Johnson Hospital
New Brunswick, New Jersey, 08901, United States
NCT Number: NCT06899191
The goal of this clinical trial is to improve the processes of Type 2 Diabetes (T2D) care coordination and treatment in the emergency department (ED) by utilizing clinical decision support mechanisms in the electronic health record (EHR). The main question is whether electronic prompts triggered by hyperglycemia and elevated A1c results in providers providing earlier treatments and faster time to subsequent primary care appointment and greater reduction in hemoglobin A1c (HA1c).
ED clinicians will receive alerts called Our Practice Advisories (OPA's) through the EPIC EHR. The 1st OPA triggers when a random point-of-care (POC) glucose is ≥250 mg/dL, prompting a suggested additional HA1c order. A 2nd OPA triggers if the resulting HA1c is ≥10%, prompting consideration of further care coordination in the Observation Unit. Investigators will compare the outcomes post-intervention compared to pre-intervention.
Looking for future studies?
Notify Me21 year and older
All sexes
Interventional
Not applicable
New Brunswick, New Jersey, 08901, United States
Type 2 Diabetes (T2D) is a growing public health crisis with rates of diabetes steadily increasing over the last 10 years. The ED is commonly the first point of contact for individuals who present with symptoms of hyperglycemia, often with very severe (HbA1C > 10%) underlying diabetes. However, there is currently no national guideline or clinical policy for the ED management of patients who are not in diabetic ketoacidosis (DKA) or in a hyperglycemia hyperosmolar state (HHS). The investigators hypothesize that there are two subgroups who may benefit from greater care coordination initiated from the ED: patients who are newly-diagnosed with severe T2D and patients whom T2D is poorly-controlled despite medication adherence. This study designs electronic prompt practice advisories that nudge ED providers towards more aggressive treatment pathways. It is currently unknown whether alert tools can improve the delivery and coordination of care of patients with severe T2D presenting to the ED.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Moderate hyperglycemia, (glucose ≥250 mg/dL)
Exclusion criteria
Prompt to order A1c
Electronic prompt nudging ED provider to consider admitting patient to the Observation Unit for care coordination and more aggressive glycemic control
Time frame: From date of ED encounter until 4 weeks after
% Patients achieving: A T2D-related appointment within 4 weeks
Time frame: From date of ED encounter to 4 months after
% Patients achieving: HbA1c 1% reduction in 3 months
Time frame: Within 1 day of ED encounter date
number of patients discharged, number of patients admitted to observation unit, number of patients admitted to hospital
Time frame: 1 day
Length of stay (minutes) of subject ED encounter
Time frame: Within 3 weeks of ED encounter
Inclusion: patients with NO insurance Measure % Patients achieving new insurance
Time frame: 3 days
Inclusion: patients discharged from the ED or observation Unit
% subjects prescribed a diabetes medication
Time frame: 3 days
Inclusion: patients discharged from the ED or observation Unit
% subjects with a change in diabetes medication regimen
Time frame: 3 months
Time (days) to next appointment related to T2D, calculated as [Appt date] - [ED encounter date]
Time frame: 1 day
Proportion of patients with hemoglobin A1c ordered in the ED
Time frame: 1 day
Serum glucose concentration change from beginning to end of ED encounter
Time frame: 6 months
Serum hemoglobin A1c (%)
Time frame: 1 day
Proportion of subjects with newly diagnosed Type 2 Diabetes, proportion of subjects with poorly controlled, established Type 2 Diabetes
Time frame: 1 day
% subjects receiving (1) intravenous fluids, (2) insulin, (3) other diabetes medications while in the ED
Rutgers, The State University of New Jersey
Other
Diabetes Electronic Prompt for Improved Care Coordination and Treatment (DEPICCT) in the ED
Acronym: DEPICCT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06694012
Arterial Occlusive Diseases, Arteriosclerosis
Sakai, Osaka, Japan
View Trial DetailsNCT00979628
Diabetes Mellitus, Diabetes Mellitus, Type 2
Atlanta, Georgia, United States
View Trial DetailsNCT00177398
Diabetes Mellitus, Diabetes Mellitus, Type 2
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT07650682
Autoimmune Diseases, Diabetes Mellitus
Chicago, Illinois, United States
View Trial Details